Alector Announces Pricing of Public Offering of Common Stock
- None.
- None.
The announcement by Alector, Inc. regarding its underwritten public offering of common stock is a significant financial event for the company and its investors. The decision to raise $75 million through the sale of 10,869,566 shares indicates a strategic move to bolster the company's capital. This infusion of funds is likely aimed at advancing Alector's clinical programs and potentially accelerating the development of its immuno-neurology therapies.
From a financial perspective, the offering's success hinges on investor confidence in Alector's future prospects and the perceived value of its research pipeline. The market's response to this offering will reflect the aggregate sentiment regarding Alector's ability to achieve milestones and generate future revenue streams. It's also important to note that the underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase additional shares, which could indicate a safeguard against potential overestimation of demand or provide additional capital if the offering is well-received.
As a company focused on pioneering immuno-neurology, Alector's funding strategies are crucial for sustaining long-term research and development. Immuno-neurology is an emerging field that explores the intersection of immunology and neurology to develop treatments for neurodegenerative diseases. The capital raised through this public offering could be pivotal in progressing Alector's clinical trials, which are inherently resource-intensive and time-consuming.
The success of these trials and subsequent FDA approvals are critical for Alector's viability as a biotech company. The additional funds may enable the company to navigate the regulatory landscape more effectively and potentially bring novel therapies to market quicker. This is particularly important in the biotech industry where the development cycle for new treatments is lengthy and fraught with regulatory hurdles.
The biotechnology sector is known for its volatility, with company valuations heavily dependent on clinical trial outcomes and regulatory approvals. Alector's public offering represents a strategic move to secure financial stability and support its growth trajectory. The pricing of the shares and the timing of the offering will have been carefully considered to optimize investor interest while minimizing dilution of existing shareholders' equity.
Market research analysts would scrutinize the terms of the offering, including the underwriting discounts and commissions, to evaluate the fairness and competitiveness of the deal. Additionally, the use of a shelf registration statement allows Alector flexibility in timing the market, which can be advantageous in capitalizing on favorable market conditions. The ability to offer additional shares through the underwriter's option also provides a mechanism to adjust to market demand, which can be a barometer for the industry's confidence in Alector's prospects.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of
Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333- 270126) that was previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on May 1, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding Alector’s expectations regarding the closing of the offering and expected gross proceeds from the offering. Such statements are subject to numerous risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to satisfaction of customary closing conditions related to the proposed offering and other risks and uncertainties related to the offering, Alector and its business as set forth in Alector’s filings with the SEC, including the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
FAQ
What is the total gross proceeds from the public offering of Alector, Inc. (Nasdaq: ALEC)?
When is the expected closing date for the public offering of Alector, Inc. (Nasdaq: ALEC)?
Who is acting as the sole book-running manager for the public offering of Alector, Inc. (Nasdaq: ALEC)?
What is the shelf registration statement on Form S-3 related to the public offering of Alector, Inc. (Nasdaq: ALEC)?
Where can the prospectus and accompanying documents relating to the public offering of Alector, Inc. (Nasdaq: ALEC) be obtained?
